Cirrhosis, Liver
194
50
66
57
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Research Maturity
57 completed trials (29% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.6%
7 terminated out of 194 trials
89.1%
+2.6% vs benchmark
11%
21 trials in Phase 3/4
16%
9 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (194)
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
4beta-hydroxycholesterol in Cirrhosis
Erlotinib for Hepatocellular Carcinoma Chemoprevention
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.
SGLT-2 Inhibitors in the Treatment of Ascites
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Prehabilitation for Patients Awaiting Liver Transplantation
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Online Prehabilitation for Patients Awaiting Liver Transplantation
Volatile Organic Compounds for the Assessment of Liver Disease
Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy
Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Transitional Care Program for Fluid Overload in Cirrhosis
Liver Cancer Prevention Randomized Control Trial
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Cirrhotic and Non-cirrhotic Patients With Clinically Significant Portal Hypertension